Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin in high-grade pancreatic neuroendocrine tumors
NCT07121478Phase 2Enrolling by invitation
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lurbinectedin in Pancreatic neuroendocrine tumor (PanNET) and pancreatic neuroendocrine carcinoma (PNEC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall Response Rate at 24 months. Started Sep 2025; status: enrolling by invitation.
02
Drugs
lurbinectedin
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)pancreatic neuroendocrine carcinoma (PNEC)
Beyond the preview
Go deeper on NCT07121478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07121478.